Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
nenocorilant + nivolumab
- Development stage
- Unknown
- Lead developer
- Corcept Therapeutics
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Administration
- Oral, Intravenous
01
Overview
Nenocorilant + nivolumab is a combination therapy consisting of nenocorilant (CORT118335), a selective glucocorticoid receptor (GR) modulator, and nivolumab, a programmed death-1 (PD-1) blocking monoclonal antibody. Developed by Corcept Therapeutics, this combination is designed to overcome immune resistance in solid tumors. Glucocorticoid receptor activation in the tumor microenvironment can suppress immune responses and promote tumor growth; by modulating GR, nenocorilant aims to enhance the anti-tumor activity of checkpoint inhibitors like nivolumab. The combination is currently being evaluated in the Phase 2 SYNERGY study for patients with advanced solid tumors, including platinum-resistant ovarian cancer.
- Brand names
- Opdivo
- Other names
- CORT118335 + nivolumabSYNERGY study
02
Targets
PDCD1 (Programmed cell death protein 1 receptor)GR (Glucocorticoid receptor)MR (Mineralocorticoid receptor)
Beyond the preview
Go deeper on nenocorilant + nivolumab.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on nenocorilant + nivolumab.